Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry.
Ind-Swift Laboratories Ltd. went public in 1997 and now concentrates on the manufacturing of Active Pharmaceutical Ingredients (APIs).
About the Audit
The Audit on Ind-Swift Laboratories Ltd was performed on 22-23 April 2008. The Report is 33 pages long, excluding appendices. Including appendices the Report is 100 pages long.
The Audit Report provides information on the site facilities and covers a wide range of materials, including;
Acamprosate Calcium, Anastrozole, Aripiprazole, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clarithromycin, Clarithromycin Citrate, Clarithromycin Granules, Clopidogrel Besylate, Clopidogrel Hydrogen Sulphate, Donepezil Hydrochloride, Ezetimibe, Fexofenadine Hydrochloride, Flurbiprofen, Letrozole, Nateglinide, Pentazocine, Pioglitazone Hydrochloride, Quetiapine Fumarate, Ranolazine, Risedronate Sodium, Ropinirole Hydrochloride, Venlafaxine Hydrochloride.